By 2034, the global ivermectin market could land anywhere between $2.66 billion, under Contrive Datum Insights' bear-case scenario, and $3.44 billion, under its bull case. The firm sets out both boundaries, along with its central forecast, in a new report titled "Ivermectin Market Size, Share & Industry Analysis, By Type (Injection, Powder, Others), Application (Cow, Sheep, Pig, Poultry, Others), End use (Veterinary and Animal Health, Human Health), Distribution channel (Veterinary Hospitals and Clinics, Retail Pharmacies and Agrovet Stores, Online Pharmacies, Direct and Institutional Sales), Product form (Active Pharmaceutical Ingredient (API), Formulated Products), and Regional Forecast, 2026-2034."
The central forecast puts the market at $1.65 billion in 2025, $1.76 billion in 2026, and $3.03 billion by 2034, a compound annual growth rate of 7.03%. Ivermectin is a macrocyclic lactone antiparasitic, formulated as injections, oral solutions, tablets, pour-on liquids and premix powders for cattle, sheep, pigs, poultry and companion animals, and used to treat onchocerciasis, scabies and strongyloidiasis in humans. Buyers range from commercial livestock operations and veterinary clinics to agrovet and retail pharmacy chains, animal health distributors, and human-health wholesalers and public procurement bodies.
The gap between the two scenarios comes down to how fast livestock herds grow and how quickly ivermectin loses ground to substitutes. The bull case assumes herd expansion in Asia Pacific and Latin America outpaces the base case, and that premix and pour-on formulations gain buyers faster than expected, pushing volumes above the base case in every year to 2034. The bear case assumes the opposite: slower herd growth, tighter residue and registration rules in key export markets, and a faster than expected shift to alternative anthelmintics, holding volumes below the base case throughout the same period.
The scenarios diverge most sharply in Powder, the fastest-growing type line at 8.26% a year; its share of revenue rises from 29.82% in 2025 to 33% by 2034, and its value from $0.492 billion to $1 billion. Injection remains the largest type line, holding 46.18% of 2025 revenue ($0.762 billion) and 43% by 2034, but grows at only 6.15%. Cow led application demand in 2025 at 37.98% ($0.627 billion), while Poultry grew fastest at 9.68%. Veterinary and Animal Health took 78% of 2025 revenue ($1.287 billion); Human Health grew faster, at 8.53%. Retail Pharmacies and Agrovet Stores led distribution at 39.98% ($0.66 billion), while Online Pharmacies grew fastest at 14.01%. Formulated Products held 70% of 2025 revenue ($1.155 billion) against 7.76% growth for the active pharmaceutical ingredient. Asia Pacific led all regions with 33.4% of 2025 revenue ($0.551 billion), climbing to 36% by 2034 ($1.091 billion); Middle East and Africa stayed smallest, at 10.7% in 2025 and 12% in 2034. The United States remained the single largest country market, at $0.249 billion in 2025, 15.1% of global revenue.
Of the assumptions behind the spread, herd growth in Asia Pacific carries the most weight: it sets both the ceiling the bull case reaches and the floor the bear case falls to, because it acts directly on Powder, the segment already growing fastest in the base case. The report segments the market across five axes, with revenue and growth for every line in every year from 2020 to 2034, plus country-level detail across all five regions and the methodology behind each estimate. It is delivered as a PDF; a free sample is available on request.